what does a glp-1 agonist do Can one drug it all? Reviewing the expanding clinical universe of agonists Glucagon-like peptide-1 receptor: mechanisms and
Description
Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline

The FDA also raised concerns about contamination, incorrect dosages, unapproved or harmful ingredients, and counterfeit components in compounded GLP-1s

GLP-1 and its synthetic analogs have emerged as significant therapeutic agents for the management of metabolic disorders, merging glycemic control with weight loss through innovative structural and delivery breakthroughs

Zepbound shows superior weight loss results.

Mean TTR decreased by 2.1% (95% CI, -3.7% to -0.6%

Wondering about GLP-1 dosing approaches
